These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 35154154)

  • 21. Identification and validation of 174 COVID-19 vaccine candidate epitopes reveals low performance of common epitope prediction tools.
    Prachar M; Justesen S; Steen-Jensen DB; Thorgrimsen S; Jurgons E; Winther O; Bagger FO
    Sci Rep; 2020 Nov; 10(1):20465. PubMed ID: 33235258
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.
    Aparicio B; Casares N; Egea J; Ruiz M; Llopiz D; Maestro S; Olagüe C; González-Aseguinolaza G; Smerdou C; López-Díaz de Cerio A; Inogés S; Prósper F; Yuste JR; Carmona-Torre F; Reina G; Lasarte JJ; Sarobe P
    Emerg Microbes Infect; 2021 Dec; 10(1):1931-1946. PubMed ID: 34538222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T cell epitopes in SARS-CoV-2 proteins are substantially conserved in the Omicron variant.
    Choi SJ; Kim DU; Noh JY; Kim S; Park SH; Jeong HW; Shin EC
    Cell Mol Immunol; 2022 Mar; 19(3):447-448. PubMed ID: 35043006
    [No Abstract]   [Full Text] [Related]  

  • 24. Individual
    Schetelig J; Heidenreich F; Baldauf H; Trost S; Falk B; Hoßbach C; Real R; Roers A; Lindemann D; Dalpke A; Kolditz M; de With K; Bornhäuser M; Bonifacio EE; Rücker-Braun E; Lange V; Markert J; Barth R; Hofmann JA; Sauter J; Bernas SN; Schmidt AH
    Front Immunol; 2021; 12():698193. PubMed ID: 34381451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Degenerate CD8 Epitopes Mapping to Structurally Constrained Regions of the Spike Protein: A T Cell-Based Way-Out From the SARS-CoV-2 Variants Storm.
    Boni C; Cavazzini D; Bolchi A; Rossi M; Vecchi A; Tiezzi C; Barili V; Fisicaro P; Ferrari C; Ottonello S
    Front Immunol; 2021; 12():730051. PubMed ID: 34566990
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Artificial intelligence predicts the immunogenic landscape of SARS-CoV-2 leading to universal blueprints for vaccine designs.
    Malone B; Simovski B; Moliné C; Cheng J; Gheorghe M; Fontenelle H; Vardaxis I; Tennøe S; Malmberg JA; Stratford R; Clancy T
    Sci Rep; 2020 Dec; 10(1):22375. PubMed ID: 33361777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Population-Predicted MHC Class II Epitope Presentation of SARS-CoV-2 Structural Proteins Correlates to the Case Fatality Rates of COVID-19 in Different Countries.
    Liang C; Bencurova E; Psota E; Neurgaonkar P; Prelog M; Scheller C; Dandekar T
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33807854
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells.
    Parker R; Partridge T; Wormald C; Kawahara R; Stalls V; Aggelakopoulou M; Parker J; Powell Doherty R; Ariosa Morejon Y; Lee E; Saunders K; Haynes BF; Acharya P; Thaysen-Andersen M; Borrow P; Ternette N
    Cell Rep; 2021 May; 35(8):109179. PubMed ID: 34004174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2.
    Chen HZ; Tang LL; Yu XL; Zhou J; Chang YF; Wu X
    Infect Dis Poverty; 2020 Jul; 9(1):88. PubMed ID: 32741372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HLA variation and antigen presentation in COVID-19 and SARS-CoV-2 infection.
    Augusto DG; Hollenbach JA
    Curr Opin Immunol; 2022 Jun; 76():102178. PubMed ID: 35462277
    [TBL] [Abstract][Full Text] [Related]  

  • 32. T-cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
    Li Y; Wang X; Jin J; Ma Z; Liu Y; Zhang X; Su B
    J Med Virol; 2022 Aug; 94(8):3998-4004. PubMed ID: 35474581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics.
    Nagler A; Kalaora S; Barbolin C; Gangaev A; Ketelaars SLC; Alon M; Pai J; Benedek G; Yahalom-Ronen Y; Erez N; Greenberg P; Yagel G; Peri A; Levin Y; Satpathy AT; Bar-Haim E; Paran N; Kvistborg P; Samuels Y
    Cell Rep; 2021 Jun; 35(13):109305. PubMed ID: 34166618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Omicron: Call for updated vaccines.
    Li X
    J Med Virol; 2022 Apr; 94(4):1261-1263. PubMed ID: 34927258
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.
    López D
    Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In silico analysis of mutant epitopes in new SARS-CoV-2 lineages suggest global enhanced CD8+ T cell reactivity and also signs of immune response escape.
    Pretti MAM; Galvani RG; Scherer NM; Farias AS; Boroni M
    Infect Genet Evol; 2022 Apr; 99():105236. PubMed ID: 35149224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of SARS-CoV-2 specific CD4(+) and CD8 (+) T cell responses using MHC class I and II tetramers.
    Poluektov Y; George M; Daftarian P; Delcommenne MC
    Vaccine; 2021 Apr; 39(15):2110-2116. PubMed ID: 33744048
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection.
    Mahapatra SR; Sahoo S; Dehury B; Raina V; Patro S; Misra N; Suar M
    Expert Rev Vaccines; 2020 Sep; 19(9):871-885. PubMed ID: 32869699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccinomic approach for novel multi epitopes vaccine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).
    Almofti YA; Abd-Elrahman KA; Eltilib EEM
    BMC Immunol; 2021 Mar; 22(1):22. PubMed ID: 33765919
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.